Looking for the Optimal Timing of Administration of a Latency Reversing Agent to Impact on the HIV Reservoir Size
Erick De La Torre Tarazona(Instituto de Salud Carlos III), Santiago Moreno(Universidad El Bosque), Elisa Moraga(Hospital Clínic de Barcelona), Laura Luna(Instituto de Salud Carlos III), Inmaculada Jarrín(Instituto de Salud Carlos III), Luís F. López‐Cortés(Instituto de Salud Carlos III), Sergio Serrano‐Villar, José Alcamı́(Apple (Israel)), Lucio García‐Fraile(Instituto de Salud Carlos III), Elisa de Lazzari(Hospital Clínic de Barcelona), Joaquim Peraire(Instituto de Salud Carlos III), Sonsoles Sánchez-Palomino(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Raúl Vaquer(Instituto Ramón y Cajal de Investigación Sanitaria), Luz Balsalobre(Santa Lucía University General Hospital), Sònia Vicens-Artés(Hospital Clínic de Barcelona), Mercedes García‐Gasalla(Health Research Institute of the Balearic Islands)
Cited by 0
Related Papers
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel
|AIDS|2002|443
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
|The Lancet HIV|2020|396
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
|PLoS Medicine|2013|362
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
|Annals of Internal Medicine|2020|342